Business Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity
May 9, 2013
2:56 pm
HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.
Eight members of the Supreme Court heard testimony in the case of FTC v. Actavis this morning, and the fate of so-called “pay for delay” settlements hangs in the balance.
Business briefs: Gilead, Shire, The Medicines Co., HHS
February 4, 2013
7:21 pm
HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.
GlaxoSmithKline’s Dierdre Connelly peeled back the curtain on the company’s sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.
Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson & Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip.
